CCR5 and Duchenne muscular dystrophy: The system has been successfully used for targeting the human papillomavirus (HPV) 18 oncogene E6, the dystrophin gene causing Duchenne muscular dystrophy (DMD) and the HIV co-receptor C–C chemokine receptor type 5 (CCR5) [42].